中国批准Sarclisa 使用多种近视瘤,将疾病蔓延风险降低40%。 China approves Sarclisa for multiple myeloma, reducing risk of disease progression by 40%.

中国批准了Sarclisa, 一种抗CD38的药物, China has approved Sarclisa, an anti-CD38 drug, for treating adult patients with multiple myeloma who have tried at least one other therapy. 根据积极的第3阶段试验结果,批准结果表明,Sarclisa在使用pomalidomide和dexamethasone时,将疾病蔓延或死亡的风险降低40%。 The approval, based on positive phase 3 trial results, shows that Sarclisa reduces the risk of disease progression or death by 40% when used with pomalidomide and dexamethasone. 这是中国首次采用现实世界证据及临床数据进行血癌治疗。 It is the first blood cancer treatment in China approved using real-world evidence alongside clinical data.